These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 6839004)
1. Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. Kirch W; Spahn H; Ohnhaus EE; Köhler H; Heinz U; Mutschler E Biopharm Drug Dispos; 1983; 4(1):73-81. PubMed ID: 6839004 [TBL] [Abstract][Full Text] [Related]
2. The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. Houtzagers JJ; Streurman O; Regårdh CG Br J Clin Pharmacol; 1982 Jul; 14(1):67-72. PubMed ID: 6125199 [TBL] [Abstract][Full Text] [Related]
3. The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol. Regårdh CG; Lundborg P; Persson BA Biopharm Drug Dispos; 1981; 2(1):79-87. PubMed ID: 7236872 [TBL] [Abstract][Full Text] [Related]
4. Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Kirch W; Spahn H; Köhler H; Ohnhaus EE; Mutschler E Klin Wochenschr; 1982 Nov; 60(22):1401-7. PubMed ID: 7176462 [TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Seiler KU; Schuster KJ; Meyer GJ; Niedermayer W; Wassermann O Clin Pharmacokinet; 1980; 5(2):192-8. PubMed ID: 7363534 [TBL] [Abstract][Full Text] [Related]
6. Accumulation of atenolol and metoprolol in human breast milk. Liedholm H; Melander A; Bitzén PO; Helm G; Lönnerholm G; Mattiasson I; Nilsson B; Wåhlin-Boll E Eur J Clin Pharmacol; 1981; 20(3):229-31. PubMed ID: 7286041 [No Abstract] [Full Text] [Related]
7. Metabolic aspects of maximal exercise performance after slow release metoprolol and after atenolol. Folgering HT; Borm JF; van Haaren RH Eur J Clin Pharmacol; 1982 Oct; 23(4):283-8. PubMed ID: 7173299 [TBL] [Abstract][Full Text] [Related]
9. Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol. Gangji D; Juvent M; Niset G; Wathieu M; Degreve M; Bellens R; Poortmans J; Degre S; Fitzsimons TJ; Herchuelz A Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):29S-35S. PubMed ID: 6146337 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Wan SH; Koda RT; Maronde RF Br J Clin Pharmacol; 1979 Jun; 7(6):569-74. PubMed ID: 465278 [TBL] [Abstract][Full Text] [Related]
11. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol. Hallengren B; Nilsson OR; Karlberg BE; Melander A; Tegler L; Wåhlin-Boll E Eur J Clin Pharmacol; 1982; 21(5):379-84. PubMed ID: 7075643 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. Flouvat B; Decourt S; Aubert P; Potaux L; Domart M; Goupil A; Baglin A Br J Clin Pharmacol; 1980 Apr; 9(4):379-85. PubMed ID: 7378254 [TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of atenolol--a review. Kirch W; Görg KG Eur J Drug Metab Pharmacokinet; 1982; 7(2):81-91. PubMed ID: 6749509 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of atenolol in relation to renal function. Kirch W; Köhler H; Mutschler E; Schäfer M Eur J Clin Pharmacol; 1981 Jan; 19(1):65-71. PubMed ID: 7461026 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Jordö L; Attman PO; Aurell M; Johansson L; Johnsson G; Regårdh CG Clin Pharmacokinet; 1980; 5(2):169-80. PubMed ID: 6102500 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol. Spahn H; Kirch W; Mutschler E; Ohnhaus EE; Kitteringham NR; Lögering HJ; Paar D Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):97S-102S. PubMed ID: 6743480 [TBL] [Abstract][Full Text] [Related]
17. Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol. Harron DW; Balnave K; Kinney CD; Wilson R; Russell CJ; Shanks RG Clin Pharmacol Ther; 1981 Mar; 29(3):295-302. PubMed ID: 7471600 [TBL] [Abstract][Full Text] [Related]
18. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. Rigby JW; Scott AK; Hawksworth GM; Petrie JC Br J Clin Pharmacol; 1985 Oct; 20(4):327-31. PubMed ID: 2866783 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Regårdh CG; Jordö L; Ervik M; Lundborg P; Olsson R; Rönn O Clin Pharmacokinet; 1981; 6(5):375-88. PubMed ID: 7333059 [TBL] [Abstract][Full Text] [Related]
20. Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity. Ochs HR; Greenblatt DJ; Arendt RM; Schäfer-Korting M; Mutschler E Arzneimittelforschung; 1985; 35(10):1580-2. PubMed ID: 2866772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]